How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/moxifloxacin-metronidazole-or-piperacillin-tazobactam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Moxifloxacin/Metronidazole or Piperacillin/Tazobactam — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Moxifloxacin/Metronidazole or Piperacillin/Tazobactam (Moxifloxacin/Metronidazole or Piperacillin/Tazobactam) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Broad-spectrum antibiotic combination. Area: Infectious Disease.

phase 3 Broad-spectrum antibiotic combination Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Moxifloxacin/Metronidazole or Piperacillin/Tazobactam (Moxifloxacin/Metronidazole or Piperacillin/Tazobactam) — Hannover Medical School. This is a combination antibiotic regimen that uses fluoroquinolone and nitroimidazole agents (or beta-lactam with beta-lactamase inhibitor) to provide broad-spectrum coverage against aerobic and anaerobic bacteria.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Moxifloxacin/Metronidazole or Piperacillin/Tazobactam TARGET	Moxifloxacin/Metronidazole or Piperacillin/Tazobactam	Hannover Medical School	phase 3	Broad-spectrum antibiotic combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Broad-spectrum antibiotic combination class)

Hannover Medical School · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Moxifloxacin/Metronidazole or Piperacillin/Tazobactam — Competitive Intelligence Brief. https://druglandscape.com/ci/moxifloxacin-metronidazole-or-piperacillin-tazobactam. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab